8-K: Omeros Completes Convertible Note Exchange and Announces First Quarter 2025 Financial Results

Omeros Corporation completes a private exchange of convertible notes, announces an equitization transaction, and reports its first quarter 2025 financial results, highlighting a net loss and strategic prioritization of resources.

Summary

• Omeros Corporation reported a net loss of $33.5 million, or $0.58 per share, for the first quarter of 2025.
• This compares to a net loss of $37.2 million, or $0.63 per share, for the first quarter of 2024.
• As of March 31, 2025, the company had $52.4 million in cash and short-term investments.
• The company resubmitted its Biologics License Application (BLA) to the FDA for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) with a target FDA action date of September 25, 2025.
• Omeros is preparing a European marketing authorization application (MAA) for narsoplimab in TA-TMA, expected to be submitted in the second quarter of 2025.
• The company completed a private exchange of $70.8 million aggregate principal amount of its 2026 Convertible Senior Notes for newly issued 2029 Convertible Senior Notes.
• An agreement was reached with affiliated holders to convert $10 million of the 2026 Convertible Notes into common stock, to be completed by September 15, 2025.
• The company has temporarily paused certain activities and programs to prioritize resources for the potential commercial launch of narsoplimab and ongoing clinical trials.
• The Phase 3 PNH program evaluating zaltenibart has been temporarily paused, while the company continues activities in the ongoing clinical trial evaluating zaltenibart for the treatment of PNH in treatment-naive patients and to continue the long-term extension study.
• The expanded access program (EAP) for narsoplimab has been suspended, but the ongoing study of narsoplimab in pediatric patients with TA-TMA will continue.
• Development spending on OMS1029, a long-acting MASP-2 inhibitor, has been limited, and spending in other areas of the complement programs is being reduced or halted.
• OMIDRIA royalties for the first quarter of 2025 were $6.7 million on Rayner's U.S. net sales of $22.3 million, compared to $9.4 million on U.S. net sales of $31.2 million in the first quarter of 2024.
• Total operating expenses for the first quarter of 2025 were $35.0 million, a decrease of $4.1 million compared to $39.0 million for the first quarter of 2024.
• Interest expense decreased to $3.7 million in the first quarter of 2025 from $8.2 million in the prior year quarter due to debt repurchases and a non-cash remeasurement adjustment in the prior year.
• Net income from discontinued operations, net of tax, was $4.1 million in the first quarter of 2025 compared to $6.7 million in the first quarter of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the BLA resubmission and debt restructuring, the company is also facing financial challenges and has had to pause certain programs. The sentiment is neutral overall.

Positives

• The resubmission of the BLA for narsoplimab in TA-TMA and its acceptance by the FDA is a positive step towards potential regulatory approval.
• The exchange of convertible notes and the equitization transaction reduce the company's debt and near-term debt repayment obligations.
• The establishment of the Omeros Oncology Clinical Steering Committee signals a commitment to advancing the company's oncology program.
• The company is prioritizing resources for the potential commercial launch of narsoplimab, indicating a focus on near-term revenue generation.

Negatives

• The company reported a net loss of $33.5 million for the first quarter of 2025.
• Cash and short-term investments decreased by $37.7 million from December 31, 2024, to $52.4 million as of March 31, 2025.
• The company has temporarily paused certain activities and programs, including the Phase 3 PNH program evaluating zaltenibart and the expanded access program (EAP) for narsoplimab.
• OMIDRIA royalties decreased to $6.7 million in the first quarter of 2025 from $9.4 million in the first quarter of 2024.

Risks

• The FDA may not approve the BLA for narsoplimab in TA-TMA.
• The company may not be able to raise additional capital on favorable terms or at all.
• The company's financial condition may worsen if it is unable to generate sufficient revenue or control expenses.
• The company's clinical trials may not be successful.
• The company may face intellectual property claims or competitive developments.

Future Outlook

The company is focused on obtaining approval for narsoplimab and is prioritizing spending on its launch and other key priorities. The company expects that the exchange of convertible notes and the equitization transaction will position it well to raise additional capital for its operations.

Management Comments

• Gregory A. Demopulos, M.D., Omeros Chairman and Chief Executive Officer, stated that the BLA acceptance is a significant milestone and that the company's highest priority is to obtain approval for narsoplimab.
• Dr. Demopulos also noted that the debt reduction and lower near-term debt maturities should position the company well to raise additional capital for its operations.

Industry Context

The company is operating in the biopharmaceutical industry, which is characterized by high risk and high reward. The success of the company depends on its ability to obtain regulatory approval for its products and to successfully commercialize them. The company faces competition from other companies developing treatments for similar indications.

Comparison to Industry Standards

• It is difficult to compare Omeros' results directly to industry standards without knowing the specific stage of development and focus of comparable companies.
• However, the company's net loss and cash position can be compared to other smallto mid-cap biopharmaceutical companies.
• The company's OMIDRIA royalties can be compared to other companies that have licensed or sold royalty streams on pharmaceutical products.
• The company's clinical trial progress can be compared to other companies developing treatments for similar indications, such as TA-TMA, PNH, and AML.
• Companies like Alexion Pharmaceuticals (now part of AstraZeneca) and BioCryst Pharmaceuticals are key competitors in the complement-mediated disease space.
• For oncology, companies like Novartis and Pfizer have established AML portfolios.

Stakeholder Impact

• Shareholders may be concerned about the company's financial performance and the temporary pause of certain programs.
• Employees may be affected by the company's cost-cutting measures and prioritization of resources.
• Patients with TA-TMA may benefit from the potential approval of narsoplimab.
• Patients with PNH may be affected by the temporary pause of the Phase 3 program evaluating zaltenibart.
• Creditors may be affected by the company's debt restructuring and potential capital raise.

Next Steps

• The company will continue to respond to FDA information requests related to the narsoplimab BLA.
• The company will prepare and submit a marketing authorization application (MAA) with the EMA for narsoplimab in TA-TMA.
• The company will work to secure additional capital to fund its operations and restart the Phase 3 PNH program evaluating zaltenibart.
• The company will continue to progress pre-clinical studies within its novel oncology program, including IND-enabling studies in its OncotoX-AML program.
• The company expects to begin enrollment in the Phase 1b clinical trial for OMS527 in cocaine use disorder later this year.

Key Dates

Keywords

Omeros, narsoplimab, TA-TMA, Convertible Notes, Zaltenibart, OMS527, Oncology, Financial Results, BLA, MAA, PNH, FDA, Clinical Trials, Debt